Ascendis Pharma AS (ASND)
125.61
+0.33
(+0.26%)
USD |
NASDAQ |
Nov 04, 16:00
125.66
+0.06
(+0.04%)
After-Hours: 20:00
Ascendis Pharma EPS Diluted (Quarterly): -2.057 for June 30, 2024
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -2.057 |
| March 31, 2024 | -2.498 |
| December 31, 2023 | -1.658 |
| September 30, 2023 | -3.136 |
| June 30, 2023 | -2.355 |
| March 31, 2023 | -2.127 |
| December 31, 2022 | -3.783 |
| September 30, 2022 | -3.052 |
| June 30, 2022 | -1.555 |
| March 31, 2022 | -2.480 |
| December 31, 2021 | -2.139 |
| September 30, 2021 | -1.733 |
| June 30, 2021 | -3.013 |
| March 31, 2021 | -1.410 |
| December 31, 2020 | -3.148 |
| September 30, 2020 | -2.701 |
| June 30, 2020 | -2.170 |
| March 31, 2020 | -1.457 |
| December 31, 2019 | -1.882 |
| September 30, 2019 | -0.5893 |
| June 30, 2019 | -1.404 |
| March 31, 2019 | -1.409 |
| Date | Value |
|---|---|
| December 31, 2018 | -0.8671 |
| September 30, 2018 | -0.9418 |
| June 30, 2018 | -0.6567 |
| March 31, 2018 | -1.314 |
| December 31, 2017 | -1.083 |
| September 30, 2017 | -1.223 |
| June 30, 2017 | -1.034 |
| March 31, 2017 | -0.8309 |
| December 31, 2016 | -0.5502 |
| September 30, 2016 | -0.8036 |
| June 30, 2016 | -0.5988 |
| March 31, 2016 | -0.9046 |
| December 31, 2015 | -0.5361 |
| September 30, 2015 | -0.3334 |
| June 30, 2015 | -0.6962 |
| March 31, 2015 | 0.0677 |
| December 31, 2014 | -0.3715 |
| September 30, 2014 | -0.1549 |
| June 30, 2014 | -0.2715 |
| March 31, 2014 | -0.0637 |
| December 31, 2013 | 0.2841 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
-3.783
Minimum
Dec 2022
-1.410
Maximum
Mar 2021
-2.334
Average
-2.170
Median
Jun 2020
EPS Diluted (Quarterly) Benchmarks
| Evaxion Biotech AS | -0.40 |
| Adaptimmune Therapeutics PLC | 0.24 |
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | -3.785 |
| Genfit SA | -- |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -117.77M |
| Revenue (Quarterly) | 38.76M |
| Total Expenses (Quarterly) | 182.25M |
| Enterprise Value | 7.930B |
| Gross Profit Margin (Quarterly) | 68.15% |
| Profit Margin (Quarterly) | -303.9% |
| Earnings Yield | -7.44% |
| Normalized Earnings Yield | -7.440 |